BioSpace News Archive

AngioDynamics, Inc. (NASDAQ: ANGO) today announced the enrollment of the first patient in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV).

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 24, 2022.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on October 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to 12 individuals hired by Adicet in October 2022.

Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced it has completed the buildout of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China.

Neogen Corporation (NASDAQ: NEOG) announced today that it has added a ready-to-use chemiluminescent substrate to the trusted K-Blue® product line.

Fianostics GmbH in Austria has launched new COVID-19 antibody test kits that include Mitra® devices from Neoteryx, the microsampling brand of Trajan Scientific and Medical.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced today it has received CE marking for their BiWaze® Cough system in accordance with European Union’s Medical Device Regulation (MDR) 2017/745.

Broncus is pleased to announce that on October 28, 2022, the Company’s innovative product in the field of drug-device combination, “Mist FountainTM” (the “Product” or “Nebulizing Micro-Catheter”), a disposable nebulizing micro-catheter for endoscope, has been officially approved for marketing by Zhejiang Medical Products Administration.

Palatin Technologies, Inc. announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 1,818,182 shares of its common stock and warrants to purchase up to an aggregate of 1,818,182 shares of common stock, at a purchase price of $5.50 per share and accompanying warrant.

Bristol Myers Squibb (NYSE: BMY) today announced the COMMANDS study, a Phase 3, open-label, randomized trial evaluating Reblozyl.